Related Experiment Video
Updated: May 20, 2026
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
A sharp fluctuation in peripheral blood cells shortly after dasatinib administration
Jun Imagawa1, Hideo Tanaka, Kana Matsumoto
1Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, Japan.
International Journal of Hematology
|July 17, 2012
Summary
Dasatinib treatment transiently alters peripheral blood counts, increasing white blood cells and decreasing platelets. This tyrosine kinase inhibitor affects adhesion molecule expression, influencing blood cell distribution.
Area of Science:
- Pharmacology
- Hematology
- Oncology
Background:
- Dasatinib is a tyrosine kinase inhibitor with a short plasma half-life.
- It targets Src family kinases and has a broad inhibition profile.
- Understanding dasatinib's effects on peripheral blood counts is crucial.
Purpose of the Study:
- To investigate the impact of dasatinib on peripheral blood cell counts.
- To correlate changes in blood cell counts with dasatinib serum concentrations.
- To compare dasatinib's hematological effects with imatinib and nilotinib.
Main Methods:
- Monitoring peripheral blood counts and dasatinib serum levels over time.
- Comparing pre-dose and 2-hour post-dose blood counts in 23 patients.
- Assessing expression of adhesion molecules (CD18, CD62P, CD63) in vitro and in vivo.
Main Results:
- Dasatinib administration led to a significant increase in white blood cells (WBCs) and a decrease in platelets.
- These transient fluctuations in blood cell counts correlated with dasatinib levels.
- Unlike imatinib or nilotinib, dasatinib attenuated CD18, CD62P, and CD63 expression on blood cells.
Conclusions:
- Dasatinib influences peripheral blood cell distribution.
- The drug's effect on adhesion molecule expression may mediate these hematological changes.
- Dasatinib exhibits distinct hematological effects compared to other tyrosine kinase inhibitors like imatinib.
